Fabtech Q3 FY26: 9M revenue up 32%, Q3 posts loss of Rs 5.7 crore

Revenue growth above 20%Net loss reportedExceptional itemEBITDA margin compressionResults View source PDF Explain this filing

FABTECH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹163.56

prior close

₹154.15

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+3.7%-9.6% vs market

Medical Equipment & Supplies peers, median of 13sector+3.8%-9.7% vs sector

On the reaction day the stock moved 9.6 pts less than Nifty Microcap 250 and 9.7 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-6.0

10m

-8.0

15m

-7.2

30m

-3.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9+3.7-9.6+3.8-9.7

Next day

-10.4+5.1-15.5+3.6-14.0

-6.5+4.0-10.5+3.0-9.4

-4.6+3.2-7.8+2.9-7.5

+0.1+5.9-5.8+1.8-1.7

+3.8+6.9-3.2+3.1+0.7

+1.5+5.9-4.4+4.6-3.1

15d

-4.0+2.1-6.1+0.5-4.6

-12.6-3.5-9.1-2.9-9.7

-10.7-4.2-6.5-6.3-4.4

+1.6+10.9-9.3+4.1-2.5

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fabtech Q3 FY26 consolidated revenue fell 40% YoY to Rs 62.76 crore with a net loss of Rs 5.68 crore (vs profit Rs 20.46 crore). 9M FY26 revenue grew 32% to Rs 252.25 crore but PAT dropped 48% to Rs 16.30 crore. Standalone 9M PAT was Rs 13.71 crore. Exceptional gain of Rs 1.77 crore from subsidiary stake sale. Board dissolved Risk Management Committee.

Likely market impact

Mixed quarter: strong 9M revenue growth overshadowed by sharp Q3 loss and falling margins. Newly listed (Oct 2025); watch for sequential recovery.